Every AXLRx Sickle Cell Disease report, across 9 report types and 3 markets. Each is scoped to your asset and verified to a live source.
Gene-therapy access at $2.2–3.1M, the CMS Cell & Gene Therapy Access Model, VOC-freedom endpoints, and the hydroxyurea step-edit.
Two Dec-2023 gene therapies (Casgevy, Lyfgenia) reset a ~100,000-patient market, while voxelotor's 2024 withdrawal thins the oral field.
SCD epidemiology, genotype mix, VOC and organ-damage burden, and the 22-year life-expectancy gap across the US in-market population.
Carrier-rate-adjusted epidemiology implies 140,000-200,000 KSA patients, but NPHC's structured active-management programme reaches only 8,000-10,000, a care-registration gap, not a measurement error.
Why the GCC's largest rare-disease programme by patient volume (8,000-10,000 NPHC-managed SCD patients) sits in a commercial vacuum, with crizanlizumab and voxelotor both withdrawn, ahead of 2025-26 gene therapy registration.
Two withdrawals opened a 55,000–65,000-patient white space in Sickle Cell Disease — speed, not differentiation, is the binding constraint.
GCC carries one of the highest per-capita SCD burdens globally: ~140,000 patients in Saudi Arabia alone. Both novel disease-modifiers hit regulatory trouble in 2023-2024, leaving a 25-year-old generic as the only agent with a stable market position.
An estimated 100,000 US sickle cell disease patients narrow to a 55,000-65,000-patient pool with no adequate novel therapy, while only 50-100 of the gene-therapy-eligible minority were actually treated in year one.
Crizanlizumab's EMA/MHRA withdrawal leaves a VOC-prevention gap. Casgevy's NICE recommendation is the watershed NHS gene-therapy access event — Lyfgenia has no UK regulatory status.
15,000-17,000 diagnosed UK sickle cell disease patients, universal since 1999 newborn screening, narrow to a 4,000-6,000-patient conventional-therapy gap and a separate 200-300-per-year gene-therapy-eligible pool.
Four London teaching hospitals, Barts, King's, Imperial, and Homerton, anchor roughly 6,000 of the UK's 15,000-17,000 sickle cell patients, with Birmingham Heartlands, Manchester, Bristol, and Nottingham forming the next concentration ring. That eight-centre structure is exactly the institutional signal this workbook sizes before any individual name enters it.
KFSH&RC, KAMC, and AUH are the only GCC institutions running structured adult sickle cell disease programmes across a population of 200,000-250,000 patients. That three-centre concentration, anchored by the KFSH&RC Dammam flagship and 12+ MOH regional centres in Eastern Province, is exactly the institutional signal this workbook sizes before any individual name enters it.
NICE's SCD gene therapy appraisal, potentially the largest NHS rare disease budget event in history, hinges on an annuity payment model that current NHS SCD management cost cannot yet clearly justify.
200,000-250,000 GCC-wide sickle cell disease patients (140,000-200,000 in Saudi Arabia alone), but NPHC's actively-managed registry reaches only 8,000-10,000 — the addressable near-term funnel stage within a much larger under-managed population, not a contradiction.
Europe's largest SCD population at 15,000–17,000 patients, near-universal newborn-screening diagnosis since 1999, and NICE's recommendation of Casgevy (TA1044) as the gene therapy that will define UK access to a functional cure.
Premarital screening impact, the adult transition care gap, and the gene therapy access horizon across one of the world's highest per-capita SCD burdens.
NICE recommended crizanlizumab (TA743) via managed access in 2021, then withdrew it in 2023 after the confirmatory trial failed; Casgevy (TA1044) cleared only by restructuring its £1.65M price into managed access. A new entrant inherits no reusable ICER benchmark from either.
Why NICE's rejection of crizanlizumab on price alone is the binding constraint for any new SCD agent, the 4,000-6,000 UK patients left in a post-withdrawal white space, and the WAC ceiling that decides whether you repeat that outcome.
Casgevy and Lyfgenia list at $2.2M and $3.1M, but CMS's Cell and Gene Therapy Access Model, Medicaid concentration, and a $1.5-1.9M ICER ceiling decide the realized net, not the sticker price.
GCC SCD is the largest rare-disease market in the region (200,000-250,000 patients) with zero novel SFDA-registered therapy post-withdrawal — the binding constraint is price, not competition or diagnosis.
NICE rejected crizanlizumab at £733K-1.1M per QALY even with a PAS discount. Casgevy cleared only via a 10-year annuity at £165K/year, and any new non-gene agent must land near £15-25K/year to clear that same ceiling.
At 200,000-250,000 GCC patients, US or UK list pricing is commercially impossible. NPHC's own exceptional-access threshold caps a novel agent near SAR 8,000-20,000/year, a fraction of a $2.2M gene-therapy WAC.
A ~100,000-patient US population narrows to a 55,000-65,000-patient addressable white space, but only 50-100 gene-therapy patients were actually treated in the first 12 months versus 200-300 projected.
Near-universal newborn screening puts the UK's 15,000-17,000 SCD patients on the registry with confidence, but only the 4,000-6,000 hydroxycarbamide-inadequate subset is the addressable population for a new non-gene agent.
AXLRx publishes Payer & HTA, Competitive Intelligence, Disease Landscape, Market Sizing Model, Launch Readiness, Patient Flow Model, KOL Mapping, HTA Strategy Model, and Pricing Strategy Model for Sickle Cell Disease. Each report is scoped to your asset, verified to a live source, and delivered in 72 hours.
Current Sickle Cell Disease coverage spans United States, GCC (Gulf), and United Kingdom. Additional markets can be commissioned against the same evidence standard.
Every figure is cited to a live source at the point of writing and re-checked in an independent audit pass. The latest Sickle Cell Disease reports were updated July 2026.